Haifa team finds genes that predict Parkinson’s

At present, there isn’t a single blood test to screen for or diagnose Parkinson’s.

June 3, 2012 23:39
1 minute read.
parkinsons brain 88

parkinsons brain 88. (photo credit: )


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Researchers at the Technion- Israel Institute of Technology in Haifa have identified a group of five genes in the blood that can predict whether an individual will in future develop the severe and ultimately fatal neurological condition Parkinson’s disease.

The scientists, headed by Dr. Silvia Mandel from the Rappaport Medical Faculty, published their findings in the journal Molecular Neurodegeneration and included colleagues in Israel, Germany and Italy.

Be the first to know - Join our Facebook page.

At present, there isn’t a single blood test to screen for or diagnose Parkinson’s. This makes it difficult to identify people at risk for or at an early stage of the disease.

“Finding biological signs – or biomarkers – for Parkinson’s can help diagnose it in the early stages, even before symptoms appear and monitor the effects of treatments that protect the brain,” said Mandel, who works at the Technion’s Center for Neurodegenerative Disease. “The initial aim was to determine whether among patients in the early stage a biological signature can be found to support its diagnosis.”

They used blood samples from 62 patients at the beginning of their disease and a control group of 64 healthy people. Choice of the genes was based on previous research by Mandel and Technion Prof. Moussa Youdim.

Genetic data from 30 patients in advanced stages of the disease were used to confirm the five genes as being predictive at 100 percent accuracy.

The model also fully differentiated between Parkinson’s and Alzheimer’s disease victims.

The biomarker will help diagnose individuals in the pre-symptom stage of the disease who suffer from depression, sleep disorders, hyposmia – the reduced ability to smell and to detect odors – or people who carry genetic risk factors. These are good candidates for prospective treatment neurological treatment, they said.

The biomarker would be valuable in clinical studies for identifying the sub-population of Parkinson’s patients who would react positively to treatments aimed at molecular mechanisms to which the gene group belongs.

All five genes are part of the ubiquitin-proteasome system whose involvement in the pathology of Parkinson’s disease has already been demonstrated.

The Haifa researchers believe that in the future it will be possible to integrate a blood test with brain scanning and/or biomarkers in the spinal fluid or other tissues as the gold standard not only for early diagnosis but also for differentiation between Parkinson’s and other similar motor disorders.

Related Content

August 31, 2014
Weizmann scientists bring nature back to artificially selected lab mice